Fulltext

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

Martin A 1 , Moore C , Mallon PW , Hoy J , Emery S , Belloso W Show all authors , Phanuphak P , Ferret S , Cooper DA , Boyd MA , Second Line study team

Affiliations 

  • 1 aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint-Louis, Paris, France
AIDS, 2013 Sep 24;27(15):2403-11.
PMID: 23921615 DOI: 10.1097/01.aids.0000432534.47217.b4

Abstract

To compare changes over 48 weeks in bone mineral density (BMD) between participants randomized to lopinavir/ritonavir (LPV/r) + raltegravir (RAL) or LPV/r + 2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second line therapy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications